BetterLife Pharma Secures Funding for Mental Health Treatments

BetterLife Pharma (TSE:BETR) has released an update.

BetterLife Pharma Inc. has successfully completed a non-brokered private placement, raising $175,000 through the issuance of 1.75 million units at $0.10 each, which includes common shares and full warrants exercisable within 24 months. The company is advancing in the biotech field with a focus on neuro-psychiatric and neurological treatments, including two lead compounds, BETR-001 and BETR-002, which are in preclinical stages targeting mental disorders and anxiety-related conditions.

For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.